6 results about "Limbal stem cell" patented technology

The present application provides a method for in vitro purified corneal limbal stem cells to be transdifferentiated into lens spherules, specifically, the present application inoculates corneal limbal stem cells onto a culture plate containing a Matrigel glue layer, and cultures the corneal limbal stem cells in a culture system containing Y-27632 additives in LSCM culture solution, so that lens spherule organoids can be obtained. The method of the present application can realize the rapid transdifferentiation of corneal limbal stem cells into lens spherules, so that they can be implanted into the capsular bag as seed cells for in situ regeneration of the lens.

The application discloses application of a norepinephrine inhibitor in preparation of a medicine for treating or relieving corneal limbal stem cell deficiency, and belongs to the technical field of medicines.The experiment proves that sympathetic nerves are excessively activated in a mouse model of corneal limbal stem cell deficiency, and the release of norepinephrine is increased, and the experiment proves that 6-hydroxydopamine hydrochloride can destroy sympathetic nerves to inhibit the release of norepinephrine, and a tyrosine hydroxylase inhibitor can inhibit the synthesis of norepinephrine, and both can further relieve the symptoms of corneal limbal stem cell deficiency.The norepinephrine inhibitor can improve the corneal limbal microenvironment, reduce corneal neovascularization, reduce corneal epithelialization, enhance corneal transparency and relieve corneal edema, and provides a new direction and a new way for the pathogenic mechanism and intervention target of corneal limbal stem cell deficiency, and has a wide application prospect.

The invention provides application of Mafb as a target spot in promotion of diabetic corneal epithelium injury repair, and belongs to the technical field of biological medicine. According to the application, the Mafb gene is taken as a treatment target, the repair speed of corneal epithelium injury can be obviously accelerated by over-expressing the Mafb gene in the cornea of a diabetic patient, and the expression levels of stem cell markers and cell proliferation markers in corneal epithelium tissues are obviously up-regulated. The invention also provides a recombinant adeno-associated virus AAV9-Mafb for overexpressing the Mafb gene, and the AAV9-Mafb can significantly recover the function of the corneal limbal stem cells of the diabetic mouse and promote the proliferation of corneal epithelial cells, thereby accelerating the repair of corneal epithelium injury of the diabetic mouse.

The application discloses application of PDGF-C in corneal injury repair. The application research finds that in a corneal injury model mouse in which Pdgf-c is knocked out, Pdgf-c knockout reduces the area of corneal healing in the corneal injury mouse model, and the number of corneal limbal stem cells with proliferative activity is significantly less than that of wild type mice. Through AAV-mediated PDGF-C overexpression, the proliferation of corneal limbal stem cells can be significantly promoted, and the area of corneal healing in the corneal injury mouse model is significantly increased. These results show that overexpression of PDGF-C significantly improves the ability of corneal injury healing. Therefore, the application provides a new method for treating corneal injury.

The invention provides a method for transdifferentiating corneal limbal stem cells purified in vitro into crystalline lens bodies, and particularly, the method comprises the following steps: inoculating the corneal limbal stem cells onto a culture plate containing a Matrigel glue layer, and culturing the corneal limbal stem cells in a culture system of an LSCM culture solution containing a Y-27632 additive, so that crystalline lens body organs can be obtained. According to the method disclosed by the invention, the corneal limbus stem cells can be quickly transdifferentiated into crystalline lens bodies, so that the corneal limbus stem cells can be implanted into a capsular bag to serve as seed cells for in-situ regeneration of crystalline lenses.

The invention provides application of vasoactive intestinal peptide VIP in preparation of a medicine for preventing and / or treating corneal epithelium lesion, and belongs to the technical field of biological medicine preparation. The invention discloses application of vasoactive intestinal peptide VIP in preparation of a medicine for preventing and / or treating corneal epithelium lesion. Researches show that diabetes can cause expression down-regulation of VIP and a receptor VIPR1 thereof in corneal limbus tissues, so that proliferation activity of corneal limbus stem cells of diabetic mice is reduced, and healing of corneal epithelium wounds is delayed. The exogenous supplement of VIP can effectively reverse the pathological change, significantly enhance the multiplication capacity of corneal limbal stem cells and accelerate the repair of corneal epithelium wounds; on the contrary, the VIPR1 receptor is knocked out, so that the proliferation activity of the corneal limbal stem cells is reduced, and the epithelium repair is delayed. Based on the results, the invention provides a new application of VIP in preparation of medicines for preventing and / or treating corneal epithelium lesions, and a new effective means is provided for repair treatment of the diseases.